Skip to content
Home/Companies/Biotech/Meiogenix
Meiogenix

Meiogenix

Biotech·France·Active·7yr hold
Entry
2019
Hold
7yr
Status
Active

Who owns Meiogenix?

Meiogenix is a French Biotech company, currently owned by Sofinnova Partners since 2019.

Hand-verified · updated 2026-04-21

Open JSON · CC-BY
Sofinnova Partners
Investor
Sofinnova Partners
Sofinnova Industrial Biotech · 2018 · VC

Key facts

HQFrance
SectorBiotech
Websitemeiogenix.com

More from Sofinnova Industrial Biotech

Other portfolio companies in the same fund.

P2 Science
P2 Science
Active
IndustrialsUnited States· 2026
Arzeda
Arzeda
Active
BiotechUS· 2022
IB Works I
Exited 2024
SoftwareFrance· 2022
Prometheus Materials
Prometheus Materials
Active
BiotechUS· 2022
Novameat
Novameat
Active
BiotechSpain· 2021
Qorium
Qorium
Active
BiotechNetherlands· 2021

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Meiogenix?

Meiogenix is currently owned by Sofinnova Partners, through Sofinnova Industrial Biotech, since 2019.

When did Sofinnova Partners acquire Meiogenix?

Sofinnova Partners acquired Meiogenix in 2019.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue